

Self · LIGAND PHARMACEUTICALS INC · Ligand Pharmaceuticals Incorporated - Common Stock
Purchase
Disclosed range starting at $1K
Disclosed 10 days after execution (STOCK Act deadline: 45)
3 prior trades recorded in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 25 | Aryeh JasonDirector | Open-market sale | SELL | $90K 282 sh | Nov 6, 2026 traded Nov 4, 2026 | |
| 2 | Reardon AndrewCLO & Secretary | Option exercise · 10b5-1 plan | M | $261K 5,000 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 3 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $25K 80 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $140K 440 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $198K 634 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $64K 200 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $162K 522 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $126K 403 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $102K 320 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $87K 283 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $152K 490 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 0 | Reardon AndrewCLO & Secretary | Option exercise · 10b5-1 plan | M | — 5,000 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 3 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $39K 120 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $218K 708 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $89K 280 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 6 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $162K 520 sh | Nov 4, 2026 traded Nov 2, 2026 | |
| 0 | Reardon AndrewCLO & Secretary | Option exercise · 10b5-1 plan | M | $18K 340 sh | Oct 6, 2026 traded Oct 2, 2026 | |
| 4 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $252K 833 sh | Oct 6, 2026 traded Oct 2, 2026 | |
| 1 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $72K 235 sh | Oct 6, 2026 traded Oct 2, 2026 | |
| 0 | Reardon AndrewCLO & Secretary | Open-market sale · 10b5-1 plan | SELL | $5,232 17 sh | Oct 6, 2026 traded Oct 2, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.
= $8,001
Gilbert Ray Cisneros, Jr. reported a purchase of Ligand Pharmaceuticals Incorporated - Common Stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.
Recorded votes from the House Clerk and Voteview (Senate). Listed by date; a vote near a trade is not evidence the two are related.